You are here: Industry Insights > Remicade

News List

FDA Approves Avsola (infliximab-axxq), a Biosimilar to Remicade drugs
December 11, 2019
Amgen announced that the U.S. Food and Drug Administration (FDA) has approved Avsola (infliximab-axxq) for all approved indications of the reference product, Remicade® (infliximab) ...
FDA Approves AVSOLA americanpharmaceuticalreview
December 11, 2019
Amgen announced the U.S. Food and Drug Administration (FDA) has approved AVSOLA™ (infliximab-axxq) for all approved indications of the reference product, Remicade® (infliximab)
Financial Report: Johnson & Johnson contractpharma
April 19, 2019
Pharmaceutical sales up 4% in the quarter despite declines for REMICADE and ZYTIGA.
As competition heats up, U.S. prices for Remicade and biosims slip: analyst fiercepharma
December 12, 2018
As Johnson & Johnson vies with biosimilars to its big-selling Remicade, prices across the category are gradually falling, an analyst says—and Pfizer's Inflectra has taken the biggest tumble.
EU nod for Sandoz’ Remicade biosimilar Zessly pharmatimes
July 11, 2018
The European Commission has green-lighted Novartis unit Sandoz’ Zessly, a biosimilar version of Johnson & Johnson and Merck's Remicade.
US regulators approve Pfizer’s Remicade biosimilar pharmatimes
December 18, 2017
The US Food and Drug Administration has issued a green light for Pfizer’s biosimilar of Janssen’s mega blockbuster Remicade.
Pfizer files lawsuit against J&J’s exclusionary contracts for Remicade pharmaceufical-technology
September 22, 2017
Pfizer has filed a lawsuit against Johnson & Johnson (J&J) in the US District Court for the Eastern District of Pennsylvania to ensure patients and providers have access to major, lower-cost biosimilar therapies.
Merck launches Remicade biosimilar for all eligible indications, in the US cphi-online
July 26, 2017
The biosimilar's list price will represent a 35% discount to the current list price of Remicade.